This is a retrospective cohort study, aiming at analyzing the efficacy and safety of mesh surgery in pelvic organ prolapse. The synthetic mesh for pelvic organ prolapse include transvaginal mesh or laparotomy, laparoscope, or robotic-assisted laparoscopic sacrocolpopexy with mesh augmentation. The investigators would like to evaluate the efficacy and safety, such as recurrence rates and complication rates for women who underwent urogynecology mesh surgery.

Gynecologic mesh, including transvaginal mesh and mesh used in abdominal or laparoscopic sacrocolpopexy, has been used for pelvic organ prolapse since its debut in the US in 2005. It provides higher success and satisfaction rate than traditional colporrhaphy, but mesh-related complications, such as pain, mesh exposure and bleeding, have been reported. U.S. Food and Drug Administration issued a Safety Update in 2011 to inform the public that serious complications associated with synthetic mesh for the transvaginal repair of POP were common. Taiwan FDA and associated committees decided that the use of gynecologic mesh should be regulated. Thorough study and evaluation are needed.

Inclusion Criteria:

• Pelvic organ prolapse patients with objective / subjective voiding dysfunctions
• Underwent surgery for symptomatic POP ≥ stage II (POP-Q system)

Exclusion Criteria:

• Patients with a history of pelvic radiation.
• Patients with a history of vesico-/recto-/urethra-vaginal fistula
• Patients unable to be followed up.

History of POP patients with concurrent objective and/or subjective voiding dysfunctions who underwent primary TVM surgery for symptomatic POP

≥ stage II (POP Quantification system; POP-Q system) in Mackay Memorial Hospital were recruited.

For we uncertain if this might violate personal information laws in our country.